Latest cardiac arrhythmia Stories
Montgomery Heart & Wellness, a sponsor of the Third Annual Houston Town Hall Meeting, commends residents for their support and active participation in the meeting. Houston, TX (PRWEB) October 31, 2011 Sponsored by Montgomery Heart & Wellness, Boston Scientific Corporation’s Close the Gap, Advanced Nuclear Consultants and the Johnsie and Aubary Montgomery (JAM) Institute of Medical Education and Research based out of Houston, Texas, this year's meeting focused on the...
Professor Borggrefe from University Hospital of Mannheim presented an implantation case of Impulse Dynamic's Optimizer III CCM device, performed by Dr. Kuschyk, at VENICE ARRHYTHMIAS 2011, Venice. Venice, Italy (PRWEB) October 27, 2011 A CCM device implantation case was presented last week at the Venice Arrhythmia conference as part of a new device technologies session. The implantation was performed by Dr. Kuschyk at the University Hospital of Mannheim in Germany one year ago. The...
TIANJIN, China, Oct. 27, 2011 /PRNewswire-Asia/ -- On October 18, 2011, the "TICH- BIOTRONIC Pacemaker Wireless Monitoring Services Centre" was co-founded at Teda by TEDA International Cardiovascular Hospital (hereinafter referred to as "TICH") of Tianjin, China and BIOTRONIK (Beijing) SE & Co. KG of Germany. This center is the first institution in China which engages the professional medical staff for the online monitoring of the conditions of patients with implanted pacemaker, ICD...
New research has the potential to revolutionize the treatment of atrial fibrillation (AF), a condition affecting a quarter of a million Canadians which is expected to strike even more in the coming years, as the Canadian population ages. AF is the most common type of heart arrhythmia and puts those affected at a three to five times greater risk for stroke. Now, there is a new drug poised to battle the condition. "The majority of patients with atrial fibrillation need an anticoagulant....
MORRISVILLE, N.C., Oct. 26, 2011 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, announced today the launch of its new corporate websites, www.ncontactinc.eu and www.ncontactinc.com. The design of the new corporate sites reflects the evolution of nContact's technology and the market for treating cardiac arrhythmias that affect millions of people worldwide. "The new websites are excellent educational references that highlight how our technology is being...
(Ivanhoe Newswire) – Atrial fibrillation (AF) is the most common type of heart arrhythmia that causes five times greater risk for stroke. A new drug has the potential to revolutionize the treatment of AF and battle the deadly disorder. "The majority of patients with atrial fibrillation need an anticoagulant. The current anticoagulant can be a burden for physicians and patients due to its side effects and narrow therapeutic range," Dr. Justin Ezekowitz, from the University of Alberta, was...
ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Treating patients with the new blood thinning medication dabigatran (Pradaxa®), instead of warfarin results in significantly higher per patient costs and higher net costs per stroke avoided, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime).The study will be presented today at the Academy of Managed Care Pharmacy's Educational Conference in Atlanta, Ga. Dabigatran is a type of blood-thinning medication used to...
MARLBOROUGH, Mass., Oct. 12, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight(TM) Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its HeartLight EAS was used to achieve successful acute PV isolation and restore sinus rhythm in a persistent AF patient during a live case at the Venice Arrhythmias 2011 conference, October 9-12 in Venice, Italy. Additionally, research presented during the scientific sessions further supports the...
(Ivanhoe Newswire) -- Painful jolts are so yesterday! Each year in the United States, more than 200,000 people have a cardiac defibrillator implanted in their chest to deliver a high-voltage shock to prevent sudden cardiac death from a life-threatening arrhythmia. While it is a necessary and effective preventive therapy, those who have experienced a defibrillator shock say it is painful, and some studies suggest that the shock can damage heart muscle. Scientists at John Hopkins believe...
DALLAS, Sept. 28, 2011 /PRNewswire/ -- September 2011 is the fifth annual Atrial Fibrillation Awareness Month. Raising afib awareness is intensely personal for StopAfib.org founder Mellanie True Hills and led her to create the first Atrial Fibrillation Awareness Month in 2007. Working with other organizations, Hills helped urge the U.S. Senate to officially designate National Atrial Fibrillation Awareness Month in September 2009. For Hills, a highlight of Afib Month 2011 was the privilege...
